Furthermore, anti-TNF-α antibody therapy is linked to side effects such as sarcoidosis, uveitis, and nervous system disorders; and immunosuppression associated with TNF-α blockade is a significant risk factor for exacerbation of disease pathology in SARS-CoV-2 infected individuals (69–71). This evidence concerns the gene TNF and uveitis.